BioSpace News Archive

Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced that management will participate in a fireside chat at the Jefferies 13th Annual London Healthcare Conference in London, UK.

Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2022.

Pear Therapeutics, Inc. announced results from a retrospective analysis to evaluate the impact of Somryst® on healthcare resource use.

Sesen Bio (Nasdaq: SESN ) today reported operating results for the third quarter ended September 30, 2022, and provided a business update.

Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST to review its third quarter 2022 financial results and provide an update on the company.

Cutera, Inc., a leading provider of aesthetic and dermatology solutions, announces that AviClear is now broadly available to physicians and practitioners treating patients throughout North America.

Aphaia Pharma announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

CorMedix Inc. announced that the Center for Medicare & Medicaid Services has published in the Federal Register a correction to the Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals New Technology Add on Payment reimbursement of DefenCath, increasing the maximum reimbursement per average hospital visit from $4,387.50 to $14,259.38.

NovoMedix, LLC (“NovoMedix”), a biotechnology company developing novel, multi-pathway modulators for fibrosis and cancer, today announced the presentation of new preclinical data on NMX2 at the 2022 American Heart Association Scientific Session, being held November 5-7, 2022 in Chicago, Illinois.